Immunocore Holdings plc (NASDAQ:IMCR) Receives $73.00 Consensus Target Price from Brokerages

Posted by on Apr 24th, 2023

Shares of Immunocore Holdings plc (NASDAQ:IMCR – Get Rating) have received an average recommendation of “Buy” from the thirteen research firms that are covering the firm, Marketbeat Ratings reports. Thirteen equities research analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $73.00.

IMCR has been the topic of a number of analyst reports. Bryan, Garnier & Co started coverage on Immunocore in a research report on Friday, March 24th. They issued a “buy” rating and a $16.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $90.00 price target on shares of Immunocore in a research note on Wednesday, April 19th. Guggenheim assumed coverage on shares of Immunocore in a research report on Thursday, March 30th. They issued a “buy” rating and a $85.00 price target for the company. Oppenheimer raised their price objective on Immunocore from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, February 15th. Finally, Mizuho assumed coverage on Immunocore in a research report on Thursday, March 30th. They issued a “buy” rating and a $70.00 target price for the company.

Immunocore Price Performance

Immunocore stock opened at $61.59 on Friday. Immunocore has a 52-week low of $25.01 and a 52-week high of $69.06. The company’s 50 day moving average is $53.80 and its two-hundred day moving average is $56.36. The company has a quick ratio of 4.71, a current ratio of 4.72 and a debt-to-equity ratio of 0.24. The firm has a market cap of $2.71 billion, a PE ratio of -54.03 and a beta of 0.55.

Institutional Trading of Immunocore

Several hedge funds have recently made changes to their positions in the company. Cubist Systematic Strategies LLC raised its position in Immunocore by 20.7% in the third quarter. Cubist Systematic Strategies LLC now owns 50,688 shares of the company’s stock worth $2,379,000 after acquiring an additional 8,679 shares in the last quarter. Capital CS Group LLC purchased a new stake in shares of Immunocore during the 4th quarter worth approximately $252,000. Renaissance Technologies LLC increased its stake in Immunocore by 86.2% in the 3rd quarter. Renaissance Technologies LLC now owns 94,800 shares of the company’s stock valued at $4,450,000 after purchasing an additional 43,900 shares in the last quarter. Eschler Asset Management LLP acquired a new position in Immunocore during the third quarter worth $939,000. Finally, Logos Global Management LP purchased a new stake in Immunocore during the third quarter worth $16,429,000. Institutional investors and hedge funds own 65.11% of the company’s stock.

About Immunocore

(Get Rating)

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers.

Read More

Analyst Recommendations for Immunocore (NASDAQ:IMCR)

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.